Patient Guide to Support Services


Access 360
AZ&Me Prescription Savings Program

AstraZeneca, through its Access 360 and AZ&Me programs, offers a range of patient support programs and drug-specific patient savings programs to help patients access affordable AstraZeneca medications.

A complete list of AstraZeneca oncology medications, as well as their indications and support programs, is provided in the Table.

AstraZeneca also has a field-based team of Field Reimbursement Managers who can visit your office to provide information regarding how to access Astra­Zeneca medicines. To request a visit from a Field Reimbursement Manager in your area, call Access 360 at 844-275-2360.

AstraZeneca Access 360 Program

The Access 360 program is designed to streamline access to the company’s drugs. Access 360 provides patients and providers with affordability and reimbursement support in obtaining their medications.

The Access 360 program provides:

  • Assistance with understanding patient insurance coverage and pharmacy options
  • Prior authorization support
  • Claims and appeal process support.

A Provider Portal is available online here. AstraZeneca also offers patient savings programs for many of its drugs for eligible commercially insured patients whose insurance does not cover the full cost of their prescriptions.

AstraZeneca Access 360 specialists can help patients with commercial insurance to access drug-­specific patient support programs by identifying the patient’s prescription insurance coverage, out-of-pocket costs, and pharmacy options; and by providing support with prior authorization, insurance denial and appeals, pharmacy coordination, reimbursement, referrals to patient savings and patient assistance programs, and connections to nurse assistance or educational support programs.

Patients who are enrolled in a state or federally funded prescription insurance program are not eligible for this offer. This includes patients enrolled in Medicare Part D, Medicaid, Medigap, Veterans Affairs, Department of Defense programs, or TriCare.

AZ&Me Prescription Savings Program

The AZ&Me Prescription Savings Program is designed to help qualified patients without prescription drug coverage and a program for patients with Medicare Part D coverage.

Patients who qualify for the programs receive their AstraZeneca medicines at no cost. Patients must meet specific income eligibility criteria.


Access 360

There are no eligibility criteria to receive support from Access 360; any patient or provider can call 844-275-2360 to request support.

AZ&Me Prescription Savings Program

To be eligible for this program, patients without insurance must:

  • Meet the program’s annual household income limits
  • Reside in the United States, or have a work visa or a Green Card
  • Not receiving prescription drug coverage under a private insurance or government program, or receiving other assistance to help pay for their medicines
  • Not be eligible for Medicaid.
  • Patients who have Medicare Part D coverage must:
  • Be enrolled in a Medicare Part D plan
  • Meet the program’s annual household income limits
  • Have spent ≥3% of their total household income on prescription drugs through a Medicare Part D plan during the year
  • Reside in the United States
  • Not be eligible for Medicare’s Low Income Subsidy or for Medicaid.

Application & Enrollment

Access 360

An Access 360 Patient Authorization Form must be completed by the patient (or his/her legally authorized representative) to use most resources available through Access 360, including patient-specific support from our Field Reimbursement Managers.

You can facilitate patient authorization by:

  • Having your patient call Access 360 to provide authorization over the phone, or you can call to request a form be mailed to your patient with a self-addressed stamped envelope
  • Having your patient complete a Patient Authorization Form online at
  • Downloading and printing a PDF of the authorization form from; having your patient complete the form; and mailing it to Access 360, One MedImmune Way, Gaithersburg, MD 20878; or faxing it to 844-329-2360.
  • Patient authorization allows Astra­Zeneca to support patients with:
  • Researching your patient’s insurance coverage, out-of-pocket costs, pharmacy options, and prior authorization requirements through a comprehensive benefits investigation
  • Following up on submissions with insurers and pharmacies to provide status and obtain decisions
  • Assisting with appeals support if an insurance company denies coverage
  • Reviewing eligibility for appropriate affordability programs.

Only 1 form is required per patient, and it is valid for 2 years from the date of the patient’s signature, unless a shorter period is required by state law.

AZ&Me Prescription Savings Program

The application form for this program is available online. Patients and their prescribers must fill out the application online or by hand. The completed forms must be submitted by fax or by mail to the address listed on the form. Applications and prescriptions that are not faxed from the physician’s office will be invalid.

Patients who qualify for the program are enrolled for up to 1 year, with an option to re-enroll annually.

Table AstraZeneca Oncology Drugs

Patient support programs

Calquence (acalabrutinib)
Mantle-cell lymphoma after ≥1 previous therapies

Faslodex (fulvestrant)
HR-positive, HER2-negative advanced breast cancer in postmenopausal women who have not received endocrine therapy; HR-positive advanced breast cancer in postmenopausal women whose disease progressed after endocrine therapy; in combination with palbociclib or abemaciclib, for HR-positive, HER2-negative advanced or metastatic breast cancer that progressed after endocrine therapy

Imfinzi (durvalumab)
Locally advanced or metastatic urothelial carcinoma that progressed during or after platinum-containing chemotherapy or within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy; to reduce disease progression for patients with unresectable, stage III NSCLC that has not progressed after concurrent platinum-based chemotherapy and radiation

Iressa (gefitinib)
Metastatic NSCLC

Lumoxiti (moxetumomab pasudotox-tdfk)
Treatment of adults with relapsed or refractory hairy-cell leukemia after ≥2 systemic therapies, including a purine nucleoside analog

Lynparza (olaparib)
Maintenance treatment of recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in adults with a complete or partial response to platinum-based chemotherapy; patients with advanced ovarian cancer and deleterious or suspected deleterious germline BRCA mutation, after ≥3 chemotherapies; patients with metastatic breast cancer and germline BRCA mutation

Tagrisso (osimertinib)
Metastatic NSCLC with EGFR T790M mutation; first-line treatment of metastatic NSCLC with EGFR mutation

HR indicates hormone receptor; NSCLC, non–small-cell lung cancer.

Subscribe to
Oncology Practice Management

Stay up to date with oncology news & updates by subscribing to recieve the free OPM print publications or weekly e‑Newsletter.

I'd like to recieve: